Therapy Directory

Antibody-drug conjugates clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Antibody-drug conjugates as a study intervention. Browse Antibody-drug conjugates recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

503

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
Interventions: ALE.P03; Drug
Lead sponsor: Alentis Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 6 more

Conditions: B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, High-grade B-cell Lymphoma
Interventions: Cyclophosphamide, Fludarabine, ACE1831, Obinutuzumab; Drug
Lead sponsor: Acepodia Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Orlando, Florida • Atlanta, Georgia • Indianapolis, Indiana + 2 more

Conditions: Solid Tumor, Advanced Solid Tumor
Interventions: PYX-201; Drug
Lead sponsor: Pyxis Oncology, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 17
States / cities: Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 13 more

Conditions: Malignant Brain Neoplasm, Malignant Glioma
Interventions: Near-Infrared Fluorescence Imaging, Panitumumab, Panitumumab-IRDye800, POINPOINT-IR9000; Procedure · Biological · Drug + 1 more
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva
Interventions: Tisotumab Vedotin; Drug
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions: Bendamustine Hydrochloride, Brentuximab Vedotin; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis, Triple Negative Breast Cancer
Interventions: LY4175408, Pembrolizumab, Carboplatin, Cisplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 15
States / cities: Stanford, California • Orlando, Florida • Sarasota, Florida + 11 more

Conditions: Advanced Solid Tumor
Interventions: YL201, YL201 and atezolizumab; Drug
Lead sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 19
States / cities: Fair Oaks, California • La Jolla, California • Lone Tree, Colorado + 16 more

Conditions: Breast Cancer
Interventions: Trastuzumab Deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Miami Beach, Florida • Tampa, Florida • Boston, Massachusetts + 2 more

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 2 more

Conditions: HER2 Low Breast Carcinoma, Triple Negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions: ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride; Drug · Procedure
Lead sponsor: Laura Huppert, MD, BA; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Endometrial Carcinoma
Interventions: Sacituzumab Govitecan; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

About this Antibody-drug conjugates clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Antibody-drug conjugates as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Antibody-drug conjugates.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Antibody-drug conjugates clinical trials

Filter and sort this therapy

Live official records

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

A Study of PYX-201 in Advanced Solid Tumors

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

A Study of LY4175408 in Participants With Advanced Cancer

A Study of YL201 in Patients With Advanced Solid Tumors

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

About this Antibody-drug conjugates clinical trials directory page